BSE · 541096
Bharat Parenterals Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹57 Cr with net profit ₹1 Cr — a 2.44% net margin, versus 4.64% the period before.
Shareholding
As of 2026-06-30
- Promoter67.2%
- Public31.31%
- FII0.11%
- DII1.37%
3,059 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.89× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #17 of 50 by market cap · medians across 41 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,54,837 Cr | 66.03 | 18.46 | 25.49% | 15.55% |
| Ajanta Pharma Limited | ₹39,097 Cr | 35.66 | 8.64 | 23.33% | 19.37% |
| Gland Pharma Limited | ₹37,299 Cr | 37.55 | 3.6 | 9.92% | 15.98% |
| Rubicon Research Limited | ₹21,324 Cr | — | 16.55 | 19.14% | 14.07% |
| Eris Lifesciences Limited | ₹19,440 Cr | 54.84 | 4.98 | 15.87% | 19.89% |
| Caplin Point Laboratories Ltd. | ₹18,329 Cr | 28.38 | 5.11 | 17.88% | 29.32% |
| Marksans Pharma Limited | ₹11,427 Cr | 26.47 | 3.78 | 13.82% | 14.16% |
| Shilpa Medicare Ltd. | ₹10,683 Cr | 82.77 | 4.12 | 9.39% | 15.81% |
| Senores Pharmaceuticals Limited | ₹5,947 Cr | 45.03 | 6.37 | 12.36% | 18.32% |
| Bliss GVS Pharma Ltd. | ₹4,646 Cr | 14.69 | 3.89 | 8.95% | 11.15% |
| Bharat Parenterals Limited(this company) | ₹1,027 Cr | — | 3.2 | -2.54% | -2.37% |
AI analysis
AI-generated · google/gemini-2.5-flashBharat Parenterals Limited is listed on the Indian markets with a market capitalization of Rs 975 Cr. The company reported a revenue of Rs 352 Cr, with a dividend yield of 7% and a book value of Rs 467.55. The promoter holding stands at 67.2037% as of June 30, 2026.
Positives
- +The company has a dividend yield of 7%.
- +The promoter holding is substantial at 67.2037% as of June 30, 2026.
- +There are no reported promoter share pledges.
Negatives
- −The company reported negative annual EPS of -66.64 for March 2025.
- −The profit margin is significantly negative at -237.1%.
- −Return on Equity (ROE) is negative at -254.1%.
- −Return on Capital Employed (ROCE) is negative at -1.8265%.
- −Net profit was negative at -12.6262 Cr for the year ending March 2025.
Financial Performance
For the fiscal year ending March 2025, Bharat Parenterals Limited recorded a revenue of Rs 352.0007 Cr. The company's net profit for this period was negative at Rs -12.6262 Cr, resulting in earnings per share (EPS) of Rs -66.64. The EBITDA was also negative at Rs -21.0007 Cr for the same period.
Profitability & Returns
Bharat Parenterals Limited's profitability metrics indicate challenges, with a negative profit margin of -237.1%. The Return on Equity (ROE) was -254.1%, and Return on Capital Employed (ROCE) stood at -1.8265%. The EPS for the fiscal year ending March 2025 was -66.64.
Balance Sheet
The company's debt-to-equity ratio is 0.64. As of the latest available data, the book value per share is Rs 467.55. The company's market capitalization stands at Rs 975 Cr.
Ownership & Pledges
Promoters held 67.2037% of the shares as of June 30, 2026. Public shareholding was 31.3137%, while institutional holdings, including DII and FII, were 1.3738% and 0.1088% respectively. There were no promoter share pledges reported.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Bharat Parenterals Limitedshare price & fundamentals